Immunotherapies for non-small-cell lung cancer and mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaNeoadjuvant chemotherapy followed by radiotherapy and concurrent hyperthermia in patients with advanced-stage cervical cancer: a retrospective study
/in Cervical Cancer, Hyperthermia, International PublicationsOld and new facts about hyperthermia-induced modulations of the immune system
/in Hyperthermia, International PublicationsPhase I immunotherapy trial using glioblastoma apoptotic body-pulsed dendritic cells.
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous dendritic cell vaccine (ADCV) in combination with plasmapheresis (PP) and cyclophosphamide (Cy) in patients with disseminated melanoma: A phase II study.
/in Dendritic Cells, International Publications, Malignant MelanomaWT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia.
/in Acute Leukemia, Dendritic Cells, International PublicationsThe final report of a phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with glioblastoma.
/in Dendritic Cells, Glioblastoma, International PublicationsCorrelation of survival with tumor antigen expression in patients with newly diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell vaccine.
/in Dendritic Cells, Glioblastoma, International PublicationsCD40 ligand/interferon-γ matured DC immunization with gp100 antigen HLA class I A *0201 restricted peptides in patients with newly diagnosed metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer